Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Sigma-tau

Inverni Della Beffa Industria Chimico Farmeceutica Derivati Naturali

Piero Foresta

Maria Ornella Tinti

Vito Ulderico Ruggiero

Mauro Marzi

Domenico Misiti

Mose Santaniello

Gian Piero Moretti

Nazareno Scafetta

Patrizia Minetti

Bruno Gabetta

Aldo Cristoni

Orlando Ghirardi

Nicola Fanto

Nicola Fanto'

Marie O Tinti

2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory pathologies (particularly septic shock) and/or autoimmune pathologies in which the aetiopathogenic role of inflammatory cytokines has been ascertained.

2-aminotetralines and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies

2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies

6,7-substituted 2-aminotetralines are used to treat inflammatory and/or autoimmune conditions induced by inflammatory cytokines.

Use of 6,7-substituted 2-aminotetralines suitable for preparing a pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies

S(&minus;)-amino-6-fluoro-7-methoxytetraline, a process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock, are disclosed.

Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock

Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, staight or branched alkanoyl having 2-26 carbon atoms, optionally &ohgr;-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

Esters of acyl L-carnitines and pharmaceutical compositions containing same for treating endotoxic shock

6,7-disubstituted-2-aminotetralines of general formula (1) ##STR1## and their pharmacologically acceptable salts, wherein X and Y, identical or different are selected from the group consisting of methoxy, acetoxy and fluoro; and R and R.sub.1, identical or different, are selected from the group consisting of hydrogen, ethyl, propyl, cyclopropylmethyl, 2-hydroxy-2-phenylethyl, 2-hydroxy-2-(4-methylphenyl)ethyl and 2-hydroxy-3-(4-methoxyphenoxy)propyl are endowed with immunomodulator activity.

6,7-disubstituted-2-aminotetralines active as immunomodulators and

A therapeutical method for treating endotoxic shock which comprises administering to a patient in need thereof a (3-phthalidyliden) alkyl ester of carnitine or alkanoyl carnitine, is disclosed.

Use of Phthalidyliden esters of carnitine and alkanoyl carnitines for

6,7-disubstituted-2-aminotetralines and pharmaceutical compositions

Esters of alkanoyl L-carnitines wherein the alkanoyl is a saturated or unsaturated, straight or branched alkanoyl having 2-26 carbon atoms, optionally .omega.-substituted with trialkylammonium, dialkylsulfonium, hydroxyl, carboxyl, halogen, methanesulfonyl and hydroxysulfonyl, are useful for preparing pharmaceutical compositions for the treatment of endotoxic shock.

Esters of acyl L-carnitines and pharmaceutical compositons containing

The use of 6,7-substituted-2-aminotetralines (e.g. 2-amino-6-fluoro-7-methoxytetraline) is disclosed for preparing pharmaceutical compositions useful for the treatment of septic shock and having antiinflammatory and antipyretic activities.

Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical

Esters of acyl L-carnitines of general formula (I) ##STR1## wherein R is a straight or branched acyl group having 2 to 16 carbon atoms, in particular isobutyryl and isovaleryl;

Esters of acyl carnitines with long-chain aliphatic alcohols and

Ipoxantine derivatives of general formula (I): ##STR1## both as racemate and chiral forms and the salts thereof with pharmacologically acceptable cations, wherein n is an integer comprised between 2 and 6, and A is the residue of a dipeptide, tripeptide, tetrapeptide and pentapeptide selected, respectively, from the groups consisting of:

Growing community of inventors

Pomezia, Italy

Piero Foresta